Opus Genetics announced that its gene therapy candidate OPGx-LCA5 for Leber congenital amaurosis type 5 (LCA5), a rare inherited retinal disease causing early blindness, has been accepted into the FDA's Rare Disease Evidence Principles (RDEP) program. This acceptance supports early collaboration with the FDA on regulatory strategy and clinical trial design, aiming to streamline development and approval for this ultra-rare condition with no current treatments. OPGx-LCA5 is in Phase 1/2 trials showing promising vision improvements and has multiple FDA designations including RMAT. The company will work closely with the FDA to advance the therapy toward potential approval.
TDb Split Corp. plans a 15-for-100 share split for its Class A shares, effective for shareholders of record on July 24, 2026, pending TSX approval. Following the split, shareholders will receive the same $0.05 monthly cash distribution per share, eff...
Law Offices of Howard G. Smith reminds investors of upcoming deadlines to file lead plaintiff motions in securities fraud class actions involving Badger Meter, PicS N.V., Verra Mobility, and Grail, Inc. The lawsuits allege these companies made mislea...
Assembli Events & Production is creating the Big Ten Conference's first fan activation at Fanatics Fest NYC, held July 16-19, 2026. This event marks the Big Ten as the first collegiate conference to join the premier sports fan festival, showcasing tr...
State Street posted strong Q2 results with earnings per share of $3.65, beating estimates and up from $2.53 last year. Quarterly revenue reached $4.05 billion, driven by a 17.2% rise in fee revenues and 18% growth in net interest income. Assets under...
U.S. farmers face high and unstable fertilizer prices due to global shipping disruptions, with nearly 70% unable to afford needed fertilizer this season. Denali Water Solutions provides a natural, low-cost fertilizer alternative made from recycled or...
